Digestive Diseases and Sciences

, Volume 51, Issue 5, pp 934–941 | Cite as

Complement Activation Is Involved in Biological Responses to Leukocyte Adsorptive Apheresis

  • Shoichi Nishise
  • Yuji Takeda
  • Hiroaki Takeda
  • Katsuyoshi Ishihama
  • Tadahisa Fukui
  • Sumio Kawata
Original Paper


We examined the effects of complement activation on the biological responses of cellulose acetate (CA) beads. Peripheral blood containing the complement activation inhibitor nafamostat mesilate (NM) or heparin was incubated with CA beads in vitro. Thereafter, the fraction of adsorbed granulocytes as well as the generation of complement activation fragments (C3a and C5a) and interleukin 1 receptor antagonist (IL-1ra) were measured. Granulocyte adsorption, complement activation, and IL-1ra release were significantly inhibited in the presence of NM. Adsorption was significantly increased onto CA beads pretreated with plasma containing heparin even in the presence of NM and adding C3a or C5a enhanced IL-1ra release. These results suggested that bound complement fragment (e.g., C3b) on CA beads plays a central role in granulocyte adsorption to CA beads and that C3a and C5a augment the release of anti-inflammatory substances. We therefore conclude that complement activation is involved in these biological responses of leukocyte apheresis.


Complement activation Granulocytes Cellulose acetate beads Interleukin 1 receptor antagonist Ulcerative colitis 



We are grateful to Dr. Yuko Nishise for critically reading the manuscript, to Mr. Okio Ohnuma, Mrs. Fuyuko Kikuchi, Mrs. Makiko Sato, Mrs. Akiko Kamikawa, and Mr. Kazunori Kanouchi for excellent technical assistance, and to the volunteers who contributed blood samples.


  1. 1.
    Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 16:1–9PubMedCrossRefGoogle Scholar
  2. 2.
    Hay FC, Nineham LJ, Perumal R, Roitt IM (1979) Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis 38:1–7PubMedGoogle Scholar
  3. 3.
    Edwards SW, Hallett MB (1997) Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18:320–324PubMedCrossRefGoogle Scholar
  4. 4.
    Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRefGoogle Scholar
  5. 5.
    Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, Kasukawa R (1997) Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994PubMedGoogle Scholar
  6. 6.
    Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T (2002) Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349–2353PubMedCrossRefGoogle Scholar
  7. 7.
    Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I (2003) Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRefGoogle Scholar
  8. 8.
    Takeda Y, Hiraishi K, Takeda H, Shiobara N, Shibusawa H, Saniabadi AR, Adachi M, Kawata S (2003) Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumour necrosis factor-α or interleukin-1β in human peripheral blood. Inflamm Res 52:287–290PubMedGoogle Scholar
  9. 9.
    Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Adachi T, Shima C, Bjarnason I, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48–59PubMedCrossRefGoogle Scholar
  10. 10.
    Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K (2004) Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm Res 53:277–283PubMedCrossRefGoogle Scholar
  11. 11.
    Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMedCrossRefGoogle Scholar
  12. 12.
    Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H (2003) Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 307:146–151PubMedCrossRefGoogle Scholar
  13. 13.
    Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J (1994) Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant 9:60–66PubMedGoogle Scholar
  14. 14.
    Matata BM, Yin HQ, Courtney JM, Gaylor JD, Lamba NM, Lowe GD, Suzuki K, Kimura H, Izumi K, Klinkmann H (1996) In vitro blood compatibility evaluation of hollow fibre membrane using a controlled flow system: a comparative study. Int J Artif Organs 19:582–589PubMedGoogle Scholar
  15. 15.
    Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H, Boxer LA, Jacob HS, Hammerschmidt DE (1984) Cellulose acetate hemodialysis membranes are better tolerated than Cuprophan. A difference in complement and neutrophil activation. Contrib Nephrol 37:78–82PubMedGoogle Scholar
  16. 16.
    Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRefGoogle Scholar
  17. 17.
    Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863–2870PubMedGoogle Scholar
  18. 18.
    Stove S, Welte T, Wagner TOF, Kola A, Klos A, Bautsch W, Kohl J (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3:175–183PubMedGoogle Scholar
  19. 19.
    Bjork J, Hugli TE, Smedegard G (1985) Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134:1115–1119PubMedGoogle Scholar
  20. 20.
    Vogt W (1986) Anaphylatoxins: possible roles in disease. Complement 3:177–188PubMedGoogle Scholar
  21. 21.
    Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arth Rheum 29:1085–1089Google Scholar
  22. 22.
    Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198:913–923PubMedCrossRefGoogle Scholar
  23. 23.
    Rousseau Y, Haeffner-Cavaillon N, Poignet JL, Meyrier A, Carreno MP (2000) In vivo intracellular cytokine production by leukocytes during haemodialysis. Cytokine 12:506–517PubMedCrossRefGoogle Scholar
  24. 24.
    Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M (1984) Pharmacological studies of FUT–175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35:203–227PubMedGoogle Scholar
  25. 25.
    Ikari N, Sakai Y, Hitomi Y, Fujii S (1983) New synthetic inhibitor to the alternative complement pathway. Immunology 49:685–691PubMedGoogle Scholar
  26. 26.
    Beijering RJ, ten Cate H, Nurmohamed MT, ten Cate JW (1997) Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 23:225–233PubMedCrossRefGoogle Scholar
  27. 27.
    Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y (2003) Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 59:458–462PubMedGoogle Scholar
  28. 28.
    Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334–1341PubMedCrossRefGoogle Scholar
  29. 29.
    Pfeifer PH, Kawahara MS, Hugli TE (1999) Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 45:1190–1199PubMedGoogle Scholar
  30. 30.
    Ezekowitz RAB, Hoffmann JA (1998) Innate immunity. Curr Opin Immunol 10:9–11CrossRefGoogle Scholar
  31. 31.
    Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77:5764–5768PubMedCrossRefGoogle Scholar
  32. 32.
    Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701–2705PubMedCrossRefGoogle Scholar
  33. 33.
    Kolb WP, Morrow PR, Tamerius JD (1989) Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6:175–204PubMedGoogle Scholar
  34. 34.
    Volanakis JE (1990) Participation of C3 and its ligands in complement activation. Curr Top Microbiol Immunol 153:1–21PubMedGoogle Scholar
  35. 35.
    Ueda M, Deguchi M, Takemura S, Kasamatsu Y, Yanagida K, Fukuda W, Okamoto M, Onodera H, Sugino S, Kondo M (1991) The relationship between complement C3 receptors (CR1, CR3) on polymorphonuclear leukocytes and complement fragments during hemodialysis. Nippon Jinzo Gakkai Shi 33:679–684 (in Japanese with English abstract)PubMedGoogle Scholar
  36. 36.
    Webster RO, Larsen GL, Henson PM (1982) In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest 70:1177–1183PubMedCrossRefGoogle Scholar
  37. 37.
    Nakae H, Tajimi K (2003) Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial 7:483–485PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Shoichi Nishise
    • 1
  • Yuji Takeda
    • 2
  • Hiroaki Takeda
    • 1
  • Katsuyoshi Ishihama
    • 1
  • Tadahisa Fukui
    • 1
  • Sumio Kawata
    • 1
  1. 1.Department of GastroenterologyYamagata University School of MedicineYamagataJapan
  2. 2.Japan Immunoresearch LaboratoriesTakasakiJapan

Personalised recommendations